Stock Scorecard
Stock Summary for 10x Genomics Inc - Class A (TXG) - $19.10 as of 2/25/2026 11:52:24 AM EST
Total Score
10 out of 30
Safety Score
27 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for TXG
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TXG
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TXG
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for TXG
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for TXG (27 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for TXG
Financial Details for TXG
Company Overview |
|
|---|---|
| Ticker | TXG |
| Company Name | 10x Genomics Inc - Class A |
| Country | N/A |
| Description | 10X Genomics, Inc. is a leading life science technology company dedicated to revolutionizing genomic analysis solutions that enable researchers to explore intricate biological systems with unparalleled accuracy. Based in Pleasanton, California, the company offers a comprehensive suite of cutting-edge instruments, consumables, and analytical software designed to elevate the quality and precision of genetic research. With a global footprint that spans North America, Europe, and Asia, 10X Genomics is positioned at the forefront of genomic innovation, playing a pivotal role in advancing life sciences and addressing the evolving challenges in biological research and discovery. |
| Sector Name | HEALTHCARE |
| Industry Name | HEALTH INFORMATION SERVICES |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 5/6/2026 |
Stock Price History |
|
| Last Day Price | 19.10 |
| Price 4 Years Ago | 36.44 |
| Last Day Price Updated | 2/25/2026 11:52:24 AM EST |
| Last Day Volume | 2,445,077 |
| Average Daily Volume | 2,780,560 |
| 52-Week High | 23.56 |
| 52-Week Low | 6.78 |
| Last Price to 52 Week Low | 181.71% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 268.31 |
| Sector PE | 56.78 |
| 5-Year Average PE | -40.34 |
| Free Cash Flow Ratio | 4.69 |
| Industry Free Cash Flow Ratio | 16.93 |
| Sector Free Cash Flow Ratio | 25.83 |
| Current Ratio Most Recent Quarter | 4.46 |
| Total Cash Per Share | 4.07 |
| Book Value Per Share Most Recent Quarter | 6.21 |
| Price to Book Ratio | 3.00 |
| Industry Price to Book Ratio | 3.90 |
| Sector Price to Book Ratio | 52.87 |
| Price to Sales Ratio Twelve Trailing Months | 3.67 |
| Industry Price to Sales Ratio Twelve Trailing Months | 2.74 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.77 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 116,474,000 |
| Market Capitalization | 2,224,653,400 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 76.16% |
| Reported EPS 12 Trailing Months | -0.63 |
| Reported EPS Past Year | 0.05 |
| Reported EPS Prior Year | -0.98 |
| Net Income Twelve Trailing Months | -43,544,000 |
| Net Income Past Year | -43,544,000 |
| Net Income Prior Year | -182,627,000 |
| Quarterly Revenue Growth YOY | -1.70% |
| 5-Year Revenue Growth | 16.55% |
| Operating Margin Twelve Trailing Months | -21.20% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 473,966,000 |
| Total Cash Past Year | 473,966,000 |
| Total Cash Prior Year | 344,067,000 |
| Net Cash Position Most Recent Quarter | 473,966,000 |
| Net Cash Position Past Year | 473,966,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 19,837,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 796,326,000 |
| Total Stockholder Equity Prior Year | 710,134,000 |
| Total Stockholder Equity Most Recent Quarter | 796,326,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 130,115,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 1.12 |
| Free Cash Flow Past Year | 130,115,000 |
| Free Cash Flow Prior Year | -5,729,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.19 |
| MACD Signal | 0.02 |
| 20-Day Bollinger Lower Band | 11.30 |
| 20-Day Bollinger Middle Band | 17.04 |
| 20-Day Bollinger Upper Band | 22.79 |
| Beta | 2.24 |
| RSI | 50.25 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 2/26/2026 10:17:23 AM EST |